Planet

Planet DDS 2026 Dental Outlook Reports More New Patients and Fewer No-Shows Across the Industry

Planet DDS 2026 Dental Outlook Shows More New Patients, Fewer No-Shows Across the Industry Planet DDS, a leading provider of cloud-based, enterprise-grade dental software solutions, announced the release of its 2026 Dental Industry Outlook, an annual benchmark report designed to help…

Read MorePlanet DDS 2026 Dental Outlook Reports More New Patients and Fewer No-Shows Across the Industry
C2N

C2N Diagnostics Expands to South Korea with BeauBrain Partnership for Precivity™ Tests

C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests for Alzheimer’s Diagnosis Specialty diagnostics company C2N Diagnostics has announced a strategic partnership with South Korea–based healthcare firm BeauBrain Healthcare to introduce…

Read MoreC2N Diagnostics Expands to South Korea with BeauBrain Partnership for Precivity™ Tests
United

United Therapeutics Corporation Publishes TETON-2 Phase 3 Trial Results

United Therapeutics Corporation Shares TETON-2 Phase 3 Trial Findings in The New England Journal of Medicine United Therapeutics Corporation announced that the complete findings from its Phase 3 TETON-2 clinical trial evaluating nebulized Tyvaso® (treprostinil) inhalation solution for the treatment…

Read MoreUnited Therapeutics Corporation Publishes TETON-2 Phase 3 Trial Results
Precision BioSciences

Precision BioSciences Secures U.S. Patent Allowances for PBGENE-HBV Program

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received…

Read MorePrecision BioSciences Secures U.S. Patent Allowances for PBGENE-HBV Program
Parabilis

Parabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumor Treatment

Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…

Read MoreParabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumor Treatment
Eurofins Biomnis

Eurofins Biomnis Launches Advanced LC-MS/MS Test for Cereulide Toxin Detection in Stool

Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development…

Read MoreEurofins Biomnis Launches Advanced LC-MS/MS Test for Cereulide Toxin Detection in Stool
Curatis

Curatis Grants Neupharma Exclusive Japan Rights for Corticorelin (C-PTBE-01)

Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology…

Read MoreCuratis Grants Neupharma Exclusive Japan Rights for Corticorelin (C-PTBE-01)